Drug Trial Radar · NCT05969275
Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock
Last checked: Nov 20, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
296
Planned (sponsor's estimate)
Start
Feb 14, 2024
Primary completion
Sep 30, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Ottawa Hospital Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR); Stem Cell Network; Canadian Critical Care Trials Group; Technische Universität Dresden
- First posted
- Aug 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Septic shock is associated with substantial burden in terms of both mortality and morbidity for survivors of this illness. Pre-clinical sepsis studies suggest that mesenchymal stem (stromal) cells (MSCs) modulate inflammation, enhance pathogen clearance and tissue repair and reduce death. Our team has completed a Phase I dose escalation and safety clinical trial that evaluated MSCs in patients with septic shock. The Cellular Immunotherapy for Septic Shock Phase I (CISS) trial established that MSCs appear safe and that a randomized controlled trial (RCT) is feasible. Based on these data, the investigators have planned a phase II RCT (UC-CISS II) at several Canadian academic centres which will evaluate intermediate measures of clinical efficacy (primary outcome), as well as biomarkers, safety, clinical outcome measures, and a health economic analysis (secondary outcomes).
Conditions
- Septic Shock
- Sepsis
- Pathologic Processes
- Shock
- Systemic Inflammatory Response Syndrome
- Inflammation
- Infections
Interventions
Allogeneic umbilical cord-derived human mesenchymal stromal cellsBiological
Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells
PlaceboOther
Intravenous infusion of placebo, with excipients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Days free from mechanical ventilation and/or vasopressors and/or renal replacement therapyTime frame: Through to 28 days post-randomization
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Ottawa Hospital (General Campus)
Ottawa, Ontario, Canada · Recruiting
The Ottawa Hospital (Civic Campus)
Ottawa, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.